Curis presented data from the TakeAim Leukemia study at 2023 ASH conference

Curis last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference. “We continue to be pleased with patient enrollment in the TakeAim Leukemia study and are especially pleased that the data confirm our observations to date – that emavusertib demonstrates a safe and manageable safety profile in addition to clear anti-cancer activity,” said James Dentzer, President and Chief Executive Officer of Curis. Data were presented for 92 patients treated with emavusertib monotherapy at doses ranging from 200 mg to 500 mg BID. Substantial reductions in blast counts were observed across all patient groups, irrespective of dose level, mutation status, or prior treatment history. Treatment-related adverse events of grade greater than or equal to 3 were found to be both manageable and acceptable, with no dose-limiting myelosuppression detected. In the targeted population of patients with a FLT3 mutation, evidence of clear anti-cancer activity included changes in mutational profiles that suggest disease-modifying activity. These results were observed in patients including those who had progressed on a prior FLT3 inhibitor. Among relapsed/refractory patients with FLT3 mutation who received less than or equal to 2 prior lines of treatment and had both baseline and post-treatment marrow evaluations, administering 300 mg emavusertib BID yielded compelling results. Notably, 2 out of 3 patients achieved a Complete Response with the other achieving morphological leukemia free state, indicating strong activity in patients with FLT3 mutation.